$CTNM insider trading
Over the last 12 months, Contineum Therapeutics insiders reported no purchases and 21 sales totaling $1.8M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.8M 21 events
- Events · 12m
- 21 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 2,500 | $16.01 | $40K | -12.7% | plan |
| Jul 9, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 1,040 | $16 | $17K | -0.8% | plan · 2 tranches |
| Jul 8, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 2,500 | $16 | $40K | -12.7% | plan |
| Jul 1, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 37,179 | $15.99 | $595K | -21.6% | plan · 3 tranches |
| Jun 30, 2026 | Watkins TimCMO & Head of Development · O | ▼ Sale | 10,833 | $16.02 | $174K | -54.7% | plan |
| Jun 30, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 10,000 | $16.01 | $160K | -36.7% | plan |
| Jun 1, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $13.16 | $55K | -2.9% | plan |
| May 1, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $13.12 | $55K | -2.8% | plan · 2 tranches |
| Apr 6, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $13.43 | $56K | -2.7% | plan |
| Mar 2, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $15.01 | $63K | -2.7% | plan |
| Mar 2, 2026 | Watkins TimCMO & Head of Development · O | ▼ Sale | 3,611 | $15.02 | $54K | -100% | plan |
| Feb 25, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 7,100 | $16.02 | $114K | -32.2% | plan · 2 tranches |
| Feb 25, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 8,124 | $16.02 | $130K | -4.9% | plan · 2 tranches |
| Feb 19, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 100 | $16 | $2K | -0.1% | plan |
| Feb 11, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 400 | $16 | $6K | -2.6% | plan |
| Feb 11, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 400 | $16 | $6K | -0.3% | plan |
| Feb 3, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $14.94 | $62K | -2.6% | plan · 2 tranches |
| Jan 28, 2026 | Watkins TimCMO & Head of Development · O | ▼ Sale | 3,611 | $14.18 | $51K | -100% | plan · 2 tranches |
| Jan 5, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $10.44 | $44K | -2.5% | plan · 2 tranches |
| Dec 29, 2025 | Watkins TimCMO & Head of Development · O | ▼ Sale | 3,611 | $12.06 | $44K | -100% | plan |
| Dec 23, 2025 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $12.23 | $51K | -2.5% | plan · late |
Every $CTNM filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Contineum Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CTNM feed.